Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Blue Cross Blue Shield of Michigan said it is evaluating any potential updates to the coverage process for Darzalex Faspro and there are no changes at this time.

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) — $8 million — ...

A drug shortage is when a drug manufacturer isn't able to supply enough of a drug to meet all of its Canadian orders on time. The words drug, medication and medicine are often used interchangeably.

After hours: March 6 at 4:09:36 PM EST Loading Chart for DRUG ...

Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...

a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its cardiovascular business. Roche sees high single-digit core profit growth in 2025 Roche ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...